{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T04:23:49Z","timestamp":1787631829771,"version":"build-2736575974"},"reference-count":133,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T00:00:00Z","timestamp":1605657600000},"content-version":"vor","delay-in-days":1783,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007309","name":"Japanese Society of Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007309","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2016]]},"DOI":"10.1136\/esmoopen-2016-000037","type":"journal-article","created":{"date-parts":[[2016,11,11]],"date-time":"2016-11-11T14:10:02Z","timestamp":1478873402000},"page":"e000037","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"title":["Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation Oncology"],"prefix":"10.1016","volume":"1","author":[{"given":"H.","family":"Shibata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Sekine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Araki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Iguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Osaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kinuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kodaira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Takamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Tateishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Nagakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hosaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Morioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Moriya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Yuasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Yurikusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Yomiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/esmoopen-2016-000037_bb0010","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0140-6736(14)62038-9","article-title":"Global surveillance of cancer survival 1995\u20132009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2)","volume":"385","author":"Allemani","year":"2015","journal-title":"Lancet"},{"key":"10.1136\/esmoopen-2016-000037_bb0015","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/jnci\/djt072","article-title":"Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis","volume":"105","author":"Lee","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/esmoopen-2016-000037_bb0020","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2016-000037_bb0025","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"10.1136\/esmoopen-2016-000037_bb0030","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/esmoopen-2016-000037_bb0035","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"10.1136\/esmoopen-2016-000037_bb0040","unstructured":"Acute low back problems in adults: Assessment and treatment, AHCPR Quick Reference Guides. http:\/\/www.silcom.com\/~dwsmith\/lbpqtxt.html"},{"key":"10.1136\/esmoopen-2016-000037_bb0045","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1001\/jama.1997.03540460046031","article-title":"Use of lumbar radiographs for the early diagnosis of low back pain: proposed guidelines would increase utilization","volume":"277","author":"Suarez-Almazor","year":"1997","journal-title":"JAMA"},{"key":"10.1136\/esmoopen-2016-000037_bb0050","series-title":"Current medical diagnosis and treatment 2014","author":"Papadakis","year":"2013"},{"key":"10.1136\/esmoopen-2016-000037_bb0055","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1007\/s00330-011-2221-4","article-title":"Diagnosis of bone metastases: a meta-analysis comparing 18FDG PET, CT, MRI and bone scintigraphy","volume":"21","author":"Yang","year":"2011","journal-title":"Eur Radiol"},{"key":"10.1136\/esmoopen-2016-000037_bb0060","year":"2014"},{"key":"10.1136\/esmoopen-2016-000037_bb0065","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1007\/s00259-005-1842-8","article-title":"Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer","volume":"32","author":"Nakai","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1136\/esmoopen-2016-000037_bb0070","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/jmri.22608","article-title":"Diagnostic value of whole-body magnetic resonance imaging for bone metastases: a systematic review and meta-analysis","volume":"34","author":"Wu","year":"2011","journal-title":"J Magn Reson Imaging"},{"key":"10.1136\/esmoopen-2016-000037_bb0075","series-title":"Cancer: principles and practice of oncology","first-page":"2192","article-title":"Metastatic cancer to the bone","author":"Chow","year":"2011"},{"key":"10.1136\/esmoopen-2016-000037_bb0080","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s12149-010-0393-7","article-title":"A meta-analysis of 18F-Fluoride positron emission tomography for assessment of metastatic bone tumor","volume":"24","author":"Tateishi","year":"2010","journal-title":"Ann Nucl Med"},{"key":"10.1136\/esmoopen-2016-000037_bb0085","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1080\/02841850701459783","article-title":"Percutaneous needle biopsy of the spine","volume":"48","author":"Tehranzadeh","year":"2007","journal-title":"Acta Radiol"},{"key":"10.1136\/esmoopen-2016-000037_bb0090","first-page":"759","article-title":"Accuracy of CT-guided needle biopsy of musculoskeletal neoplasms","volume":"171","author":"Dupuy","year":"1998","journal-title":"Am J Radiol"},{"key":"10.1136\/esmoopen-2016-000037_bb0095","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00256-002-0474-3","article-title":"Accuracy of CT-guided biopsies in 359 patients with musculoskeletal lesions","volume":"31","author":"Hau","year":"2002","journal-title":"Skeletal Radiol"},{"key":"10.1136\/esmoopen-2016-000037_bb0100","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.juro.2010.03.034","article-title":"Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007)","volume":"184","author":"N\u00f8rgaard","year":"2010","journal-title":"J Urol"},{"key":"10.1136\/esmoopen-2016-000037_bb0105","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s10549-011-1475-5","article-title":"Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999\u20132007)","volume":"129","author":"Yong","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1136\/esmoopen-2016-000037_bb0110","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/pcan.2011.7","article-title":"Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999\u20132006","volume":"14","author":"Sathiakumar","year":"2011","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1136\/esmoopen-2016-000037_bb0115","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/cam4.292","article-title":"New prognostic factors and scoring system for patients with skeletal metastasis","volume":"3","author":"Katagiri","year":"2014","journal-title":"Cancer Med"},{"key":"10.1136\/esmoopen-2016-000037_bb0120","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0140-6736(05)66954-1","article-title":"Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial","volume":"366","author":"Patchell","year":"2005","journal-title":"Lancet"},{"key":"10.1136\/esmoopen-2016-000037_bb0125","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1200\/JCO.2010.28.5635","article-title":"Matched pair analysis comparing surgery followed by radiotherapy and radiotherapy alone for metastatic spinal cord compression","volume":"28","author":"Rades","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2016-000037_bb0130","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1097\/01.brs.0000180401.06919.a5","article-title":"A revised scoring system for preoperative evaluation of metastatic spine tumor prognosis","volume":"30","author":"Tokuhashi","year":"2005","journal-title":"Spine"},{"key":"10.1136\/esmoopen-2016-000037_bb0135","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/00007632-200102010-00016","article-title":"Surgical strategy for spinal metastases","volume":"26","author":"Tomita","year":"2001","journal-title":"Spine"},{"key":"10.1136\/esmoopen-2016-000037_bb0140","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1053\/j.seminoncol.2007.12.005","article-title":"The role of surgery in the management of metastatic spinal tumors","volume":"35","author":"Feiz-Erfan","year":"2008","journal-title":"Semin Oncol"},{"key":"10.1136\/esmoopen-2016-000037_bb0145","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/01.blo.0000170721.07088.2e","article-title":"Function and health status in surgically treated bone metastases","volume":"438","author":"Talbot","year":"2005","journal-title":"Clin Orthop Relat Res"},{"key":"10.1136\/esmoopen-2016-000037_bb0150","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3390\/medicina46050045","article-title":"Surgical treatment of metastatic tumors of the femur","volume":"46","author":"Toliusis","year":"2010","journal-title":"Medicina (Kaunas)"},{"key":"10.1136\/esmoopen-2016-000037_bb0155","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.jse.2011.06.019","article-title":"Complications and survival after surgical treatment of 214 metastatic lesions of the humerus","volume":"21","author":"Wedin","year":"2012","journal-title":"J Shoulder Elbow Surg"},{"issue":"415 Suppl","key":"10.1136\/esmoopen-2016-000037_bb0160","doi-asserted-by":"crossref","first-page":"S230","DOI":"10.1097\/01.blo.0000093849.72468.82","article-title":"Metastatic disease of the femur: surgical treatment","author":"Ward","year":"2003","journal-title":"Clin Orthop Relat Res"},{"key":"10.1136\/esmoopen-2016-000037_bb0165","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/01.NOR.0000320543.90115.d5","article-title":"Surgical interventions for cancer patients with impending or actual pathologic fractures","volume":"27","author":"Johnson","year":"2008","journal-title":"Orthop Nurs"},{"issue":"415 Suppl","key":"10.1136\/esmoopen-2016-000037_bb0170","doi-asserted-by":"crossref","first-page":"S201","DOI":"10.1097\/01.blo.0000093842.72468.73","article-title":"Critical evaluation of Mirels\u2019 rating system for impending pathologic fractures","author":"Damron","year":"2003","journal-title":"Clin Orthop Relat Res"},{"key":"10.1136\/esmoopen-2016-000037_bb0175","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s11999-008-0200-0","article-title":"Mirels\u2019 rating for humerus lesions is both reproducible and valid","volume":"466","author":"Evans","year":"2008","journal-title":"Clin Orthop Relat Res"},{"key":"10.1136\/esmoopen-2016-000037_bb0180","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1007\/s11999-010-1326-4","article-title":"In brief: classifications in brief: Mirels\u2019 classification: metastatic disease in long bones and impending pathologic fracture","volume":"468","author":"Jawad","year":"2010","journal-title":"Clin Orthop Relat Res"},{"key":"10.1136\/esmoopen-2016-000037_bb0185","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1302\/0301-620X.86B4.14703","article-title":"Comparative analysis of risk factors for pathological fracture with femoral metastases","volume":"86","author":"Van der Linden","year":"2004","journal-title":"J Bone Joint Surg Br"},{"key":"10.1136\/esmoopen-2016-000037_bb0190","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/BOT.0b013e3181a18728","article-title":"Nonoperative treatment of thoracic and lumbar spine fractures: a prospective randomized study of different treatment options","volume":"23","author":"Stadhouder","year":"2009","journal-title":"J Orthop Trauma"},{"key":"10.1136\/esmoopen-2016-000037_bb0195","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0360-3016(02)04147-0","article-title":"Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases","volume":"55","author":"Wu","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1136\/esmoopen-2016-000037_bb0200","first-page":"CD004721","article-title":"Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy: a systematic review of the randomised trials","author":"Sze","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1136\/esmoopen-2016-000037_bb0205","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.clon.2011.11.004","article-title":"Update on the systematic review of palliative radiotherapy trials for bone metastases","volume":"24","author":"Chow","year":"2012","journal-title":"Clin Oncol"},{"key":"10.1136\/esmoopen-2016-000037_bb0210","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.radonc.2004.09.017","article-title":"Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05)","volume":"75","author":"Roos","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1136\/esmoopen-2016-000037_bb0215","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.radonc.2006.02.007","article-title":"Patients with a favourable prognosis are equally palliated with single and multiple fraction radiotherapy: results on survival in the Dutch Bone Metastasis Study","volume":"78","author":"van der Linden","year":"2006","journal-title":"Radiother Oncol"},{"key":"10.1136\/esmoopen-2016-000037_bb0220","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ijrobp.2003.10.006","article-title":"Single fraction radiotherapy is efficacious: a further analysis of the Dutch Bone Metastasis Study controlling for the influence of retreatment","volume":"59","author":"van der Linden","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1136\/esmoopen-2016-000037_bb0225","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0167-8140(03)00232-9","article-title":"Simple radiographic parameter predicts fracturing in metastatic femoral bone lesions: results from a randomised trial","volume":"69","author":"van der Linden","year":"2003","journal-title":"Radiother Oncol"},{"key":"10.1136\/esmoopen-2016-000037_bb0230","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1148\/radiol.09081698","article-title":"Percutaneous vertebroplasty for pain management in malignant fractures of the spine with epidural involvement","volume":"254","author":"Saliou","year":"2010","journal-title":"Radiology"},{"key":"10.1136\/esmoopen-2016-000037_bb0235","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.jvir.2012.08.010","article-title":"Percutaneous vertebroplasty and kyphoplasty for pathologic vertebral fractures in the Medicare population: safer and less expensive than open surgery","volume":"23","author":"Itagaki","year":"2012","journal-title":"J Vasc Interv Radiol"},{"key":"10.1136\/esmoopen-2016-000037_bb0240","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1097\/BRS.0b013e3181b77895","article-title":"Percutaneous techniques in the treatment of spine tumors: what are the diagnostic and therapeutic indications and outcomes?","volume":"34","author":"Mendel","year":"2009","journal-title":"Spine"},{"key":"10.1136\/esmoopen-2016-000037_bb0245","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1200\/JCO.2004.03.097","article-title":"Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study","volume":"22","author":"Goetz","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2016-000037_bb0250","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1148\/radiol.2412051247","article-title":"Painful metastases involving bone: percutaneous image-guided cryoablation: prospective trial interim analysis","volume":"241","author":"Callstrom","year":"2006","journal-title":"Radiology"},{"key":"10.1136\/esmoopen-2016-000037_bb0255","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2016-000037_bb0260","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinomas: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.1136\/esmoopen-2016-000037_bb0265","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2016-000037_bb0270","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1093\/annonc\/mds175","article-title":"Clinical benefit in patients with metastatic bone diseases: results of a phase 3 study of denosumab versus zoledronic acid","volume":"23","author":"Vadhan-Raj","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2016-000037_bb0275","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1097\/JTO.0b013e31826aec2b","article-title":"Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study","volume":"7","author":"Scagliotti","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1136\/esmoopen-2016-000037_bb0280","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.1998.16.6.2038","article-title":"Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate: protocol 19 Aredia Breast Cancer Study Group","volume":"16","author":"Hortobagyi","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2016-000037_bb0285","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cncr.11892","article-title":"Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"10.1136\/esmoopen-2016-000037_bb0290","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.bjc.6601663","article-title":"Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phaseIII studies","volume":"90","author":"Body","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1136\/esmoopen-2016-000037_bb0295","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pain.2004.07.011","article-title":"Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer","volume":"111","author":"Body","year":"2004","journal-title":"Pain"},{"key":"10.1136\/esmoopen-2016-000037_bb0300","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","article-title":"Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases","volume":"14","author":"Body","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2016-000037_bb0305","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.ejca.2004.03.025","article-title":"Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer","volume":"40","author":"Diel","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1136\/esmoopen-2016-000037_bb0310","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2016-000037_bb0315","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1158\/1078-0432.CCR-11-3310","article-title":"Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid","volume":"18","author":"Martin","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1136\/esmoopen-2016-000037_bb0320","first-page":"CD003474","article-title":"Bisphosphonates and other bone agents for breast cancer","volume":"2","author":"Wong","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1136\/esmoopen-2016-000037_bb0325","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/cncr.10647","article-title":"Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma","volume":"95","author":"Samson","year":"2002","journal-title":"Cancer"},{"key":"10.1136\/esmoopen-2016-000037_bb0330","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2016-000037_bb0335","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2016-000037_bb0340","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(09)70201-3","article-title":"Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials","volume":"10","author":"Dearnaley","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2016-000037_bb0345","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/esmoopen-2016-000037_bb0350","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1136\/esmoopen-2016-000037_bb0355","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma: Myeloma Aredia Study Group","volume":"334","author":"Berenson","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2016-000037_bb0360","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0140-6736(92)93075-X","article-title":"Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma: Finnish Leukaemia Group","volume":"340","author":"Lahtinen","year":"1992","journal-title":"Lancet"},{"key":"10.1136\/esmoopen-2016-000037_bb0365","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"key":"10.1136\/esmoopen-2016-000037_bb0370","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(11)70157-7","article-title":"Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial","volume":"12","author":"Morgan","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2016-000037_bb0375","first-page":"CD003188","article-title":"Bisphosphonates in multiple myeloma: a network meta-analysis","volume":"5","author":"Mhaskar","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1136\/esmoopen-2016-000037_bb0380","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1136\/esmoopen-2016-000037_bb0385","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2016-000037_bb0390","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1600-0609.2011.01599.x","article-title":"Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma","volume":"86","author":"Delforge","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1136\/esmoopen-2016-000037_bb0395","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1007\/s00066-012-0158-4","article-title":"Impact of zoledronic acid on control of metastatic spinal cord compression","volume":"188","author":"Rades","year":"2012","journal-title":"Strahlenther Onkol"},{"key":"10.1136\/esmoopen-2016-000037_bb0400","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1007\/s00776-012-0294-9","article-title":"Zoledronic acid enhances the effect of radiotherapy for bone metastases from renal cell carcinomas: more than a 24-month median follow-up","volume":"17","author":"Takeda","year":"2012","journal-title":"J Orthop Sci"},{"key":"10.1136\/esmoopen-2016-000037_bb0405","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ijrobp.2006.08.022","article-title":"Combination ibandronate and radiotherapy for the treatment of bone metastases: clinical evaluation and radiologic assessment","volume":"67","author":"Vassiliou","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1136\/esmoopen-2016-000037_bb0410","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00066-003-0978-3","article-title":"An intra-patient dose-escalation study of disodium pamidronate plus radiotherapy versus radiotherapy alone for the treatment of osteolytic metastases. Monitoring of recalcification using image-processing techniques","volume":"179","author":"Kouloulias","year":"2003","journal-title":"Strahlenther Onkol"},{"key":"10.1136\/esmoopen-2016-000037_bb0415","first-page":"691","article-title":"Zoledronic acid concurrent with either high- or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: a phase IV randomized clinical study","volume":"18","author":"Atahan","year":"2010","journal-title":"Support Care Cancer"},{"key":"10.1136\/esmoopen-2016-000037_bb0420","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1200\/JCO.2010.32.5209","article-title":"American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer","volume":"29","author":"Van Poznak","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2016-000037_bb0425","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer","volume":"21","author":"Hillner","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2016-000037_bb0430","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2016-000037_bb0435","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/annonc\/mdn526","article-title":"Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of The National Cancer Institute of Milan","volume":"20","author":"Ripamonti","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2016-000037_bb0440","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1200\/JCO.2008.16.2768","article-title":"Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients","volume":"26","author":"Kyrgidis","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2016-000037_bb0445","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1200\/JCO.2009.21.9584","article-title":"Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw","volume":"27","author":"Vahtsevanos","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5 Suppl","key":"10.1136\/esmoopen-2016-000037_bb0450","first-page":"2","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws\u20142009 update","volume":"67","author":"Ruggiero","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1136\/esmoopen-2016-000037_bb0455","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1634\/theoncologist.10-10-842","article-title":"Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 Years","volume":"10","author":"Guarneri","year":"2005","journal-title":"Oncologist"},{"key":"10.1136\/esmoopen-2016-000037_bb0460","first-page":"719","article-title":"Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review","volume":"17","author":"Diel","year":"2009","journal-title":"Support Care Cancer"},{"key":"10.1136\/esmoopen-2016-000037_bb0465","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1634\/theoncologist.11-7-841","article-title":"Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial","volume":"11","author":"Carteni","year":"2006","journal-title":"Oncologist"},{"key":"10.1136\/esmoopen-2016-000037_bb0470","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/annonc\/mdl408","article-title":"Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis","volume":"18","author":"Aguiar Bujanda","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2016-000037_bb0475","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1634\/theoncologist.2008-0227","article-title":"High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid","volume":"14","author":"Zuradelli","year":"2009","journal-title":"Oncologist"},{"key":"10.1136\/esmoopen-2016-000037_bb0480","first-page":"87","article-title":"Risk of renal failure in cancer patients with bone metastasis treated with renally adjusted zoledronic acid","volume":"20","author":"Shah","year":"2012","journal-title":"Support Care Cancer"},{"key":"10.1136\/esmoopen-2016-000037_bb0485","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"key":"10.1136\/esmoopen-2016-000037_bb0490","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/jbmr.1613","article-title":"A single-dose study of denosumab in patients with various degrees of renal impairment","volume":"27","author":"Block","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1136\/esmoopen-2016-000037_bb0495","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1248\/bpb.33.721","article-title":"Risk factors contributing to the development of hypocalcemia after zoledronic acid administration in patients with bone metastases of solid tumor","volume":"33","author":"Hanamura","year":"2010","journal-title":"Biol Pharm Bull"},{"key":"10.1136\/esmoopen-2016-000037_bb0500","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa1001086","article-title":"Fracture Intervention Trial Steering Committee; HORIZON Pivotal Fracture Trial Steering Committee: bisphosphonates and fractures of the subtrochanteric or diaphyseal femur","volume":"362","author":"Black","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2016-000037_bb0505","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","article-title":"Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors","volume":"97","author":"Brown","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/esmoopen-2016-000037_bb0510","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid","volume":"23","author":"Coleman","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2016-000037_bb0515","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cncr.23529","article-title":"Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid","volume":"113","author":"Lipton","year":"2008","journal-title":"Cancer"},{"key":"10.1136\/esmoopen-2016-000037_bb0520","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.clon.2012.11.004","article-title":"Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses","volume":"25","author":"Lipton","year":"2013","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1136\/esmoopen-2016-000037_bb0525","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1136\/esmoopen-2016-000037_bb0530","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2016-000037_bb0535","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1200\/JCO.2011.36.5791","article-title":"Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer","volume":"30","author":"Dennis","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2016-000037_bb0540","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.critrevonc.2011.12.008","article-title":"Tumour response prediction by diffusion-weighted MR imaging: ready for clinical use?","volume":"83","author":"Heijmen","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1136\/esmoopen-2016-000037_bb0545","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMp1113631","article-title":"Goal-oriented patient care\u2014an alternative health outcomes paradigm","volume":"366","author":"Reuben","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2016-000037_bb0550","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.clon.2011.04.008","article-title":"The measurement of pain","volume":"23","author":"Frampton","year":"2011","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1136\/esmoopen-2016-000037_bb0555","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1200\/JCO.2004.10.524","article-title":"Nonsteroidal anti-inflammatory drugs, alone or combined with opioids, for cancer pain: a systematic review","volume":"22","author":"McNicol","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2016-000037_bb0560","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/0269216311428528","article-title":"The role of paracetamol and nonsteroidal anti-inflammatory drugs in addition to WHO Step III opioids in the control of pain in advanced cancer: a systematic review of the literature","volume":"26","author":"Nabal","year":"2012","journal-title":"Palliat Med"},{"key":"10.1136\/esmoopen-2016-000037_bb0565","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0885-3924(98)00081-5","article-title":"The opioid-sparing effects of intravenous ketorolac as an adjuvant analgesic in cancer pain: application in bone metastases and opioid bowel syndrome","volume":"16","author":"Joishy","year":"1998","journal-title":"J Pain Symptom Manage"},{"key":"10.1136\/esmoopen-2016-000037_bb0570","first-page":"15","article-title":"Cancer-related pain and its pharmacologic management in the patient with bone metastasis","volume":"4","author":"Slatkin","year":"2006","journal-title":"J Support Oncol"},{"key":"10.1136\/esmoopen-2016-000037_bb0575","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/1097-0142(19870215)59:4<850::AID-CNCR2820590432>3.0.CO;2-1","article-title":"A validation study of the WHO method for cancer pain relief","volume":"59","author":"Ventafridda","year":"1987","journal-title":"Cancer"},{"key":"10.1136\/esmoopen-2016-000037_bb0580","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1002\/(SICI)1097-0142(19990415)85:8<1849::AID-CNCR27>3.0.CO;2-6","article-title":"Pain treatment and outcomes for patients with advanced cancer who receive follow-up care at home","volume":"85","author":"Mercadante","year":"1999","journal-title":"Cancer"},{"key":"10.1136\/esmoopen-2016-000037_bb0585","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jpainsymman.2004.02.024","article-title":"Optimization of opioid therapy for preventing incident pain associated with bone metastases","volume":"28","author":"Mercadante","year":"2004","journal-title":"J Pain Symptom Manage"},{"key":"10.1136\/esmoopen-2016-000037_bb0590","first-page":"CD004311","article-title":"Opioids for the management of breakthrough pain in cancer patients","volume":"10","author":"Zeppetella","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1136\/esmoopen-2016-000037_bb0595","first-page":"CD003347","article-title":"Radioisotopes for metastatic bone pain","author":"Roqu\u00e9 I Figuls","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1136\/esmoopen-2016-000037_bb0600","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.radonc.2005.03.003","article-title":"Radiopharmaceuticals for the palliation of painful bone metastasis: a systemic review","volume":"75","author":"Bauman","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1136\/esmoopen-2016-000037_bb0605","first-page":"538","article-title":"Targeted \u2018bone-seeking\u2019 radiopharmaceuticals for palliative treatment of bone metastases: a systematic review and meta-analysis","volume":"56","author":"D'angelo","year":"2012","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"10.1136\/esmoopen-2016-000037_bb0610","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.bone.2005.12.004","article-title":"Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases","volume":"39","author":"Storto","year":"2006","journal-title":"Bone"},{"key":"10.1136\/esmoopen-2016-000037_bb0615","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.cllc.2012.09.001","article-title":"Clinical significance of zoledronic acid and strontium-89 in patients with asymptomatic bone metastases from non-small-cell lung cancer","volume":"14","author":"Wang","year":"2013","journal-title":"Clin Lung Cancer"},{"key":"10.1136\/esmoopen-2016-000037_bb0620","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12149-013-0775-8","article-title":"Strontium-89 for prostate cancer with bone metastases: the potential of cancer control and improvement of overall survival","volume":"28","author":"Kuroda","year":"2014","journal-title":"Ann Nucl Med"},{"key":"10.1136\/esmoopen-2016-000037_bb0625","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2016-000037_bb0630","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1682\/JRRD.2007.01.0006","article-title":"Persistent benefits of rehabilitation on pain and life quality for nonambulatory patients with spinal epidural metastasis","volume":"44","author":"Ruff","year":"2007","journal-title":"J Rehabil Res Dev"},{"key":"10.1136\/esmoopen-2016-000037_bb0635","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/sj.sc.3102024","article-title":"Prognostic indicators in metastatic spinal cord compression: using functional independence measure and Tokuhashi scale to optimize rehabilitation planning","volume":"45","author":"Tang","year":"2007","journal-title":"Spinal Cord"},{"key":"10.1136\/esmoopen-2016-000037_bb0640","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1188\/04.ONF.1137-1143","article-title":"The PRO-SELF pain control program improves patients\u2019 knowledge of cancer pain management","volume":"31","author":"Kim","year":"2004","journal-title":"Oncol Nurs Forum"},{"key":"10.1136\/esmoopen-2016-000037_bb0645","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jpainsymman.2011.09.015","article-title":"The PRO-SELF(\u00a9) Pain Control Program improves patients\u2019 knowledge of cancer pain management","volume":"44","author":"Rust\u00f8en","year":"2012","journal-title":"J Pain Symptom Manage"},{"key":"10.1136\/esmoopen-2016-000037_bb0650","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1200\/JCO.2004.06.140","article-title":"Randomized clinical trial of the effectiveness of a self-care intervention to improve cancer pain management","volume":"22","author":"Miaskowski","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2016-000037_bb0655","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2648.2011.05841.x","article-title":"Do educational interventions improve cancer patients\u2019 quality of life and reduce pain intensity? Quantitative systematic review","volume":"68","author":"Ling","year":"2012","journal-title":"J Adv Nurs"},{"key":"10.1136\/esmoopen-2016-000037_bb0660","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1684\/bdc.2013.1851","article-title":"Multidisciplinary meetings dedicated to bone metastases: a historical perspective and rationale","volume":"100","author":"Vieillard","year":"2013","journal-title":"Bull Cancer"},{"key":"10.1136\/esmoopen-2016-000037_bb0665","first-page":"845","article-title":"The multidisciplinary approach to bone metastases","volume":"17","author":"Blum","year":"2003","journal-title":"Oncology (Williston Park)"},{"key":"10.1136\/esmoopen-2016-000037_bb0670","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/030089160909500304","article-title":"Multidisciplinary approach to the treatment of bone metastases: Osteo-Oncology Center, a new organizational model","volume":"95","author":"Ibrahim","year":"2009","journal-title":"Tumori"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920325825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920325825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/esmoopen-2016-000037","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:20:06Z","timestamp":1761855606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702920325825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":133,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016]]}},"alternative-id":["S2059702920325825"],"URL":"https:\/\/doi.org\/10.1136\/esmoopen-2016-000037","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation Oncology","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/esmoopen-2016-000037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 THE AUTHORS. Published by Elsevier Limited on behalf of European Society for Medical Oncology; Originally published by BMJ.","name":"copyright","label":"Copyright"}],"article-number":"e000037"}}